Maruyama Dai
Department of Hematology, National Cancer Center Hospital.
Rinsho Ketsueki. 2020;61(8):890-900. doi: 10.11406/rinketsu.61.890.
Although Hodgkin lymphoma is now among the most curable of the lymphomas, the relapse rate after the first-line treatment remains at 20-30%. Brentuximab vedotin (BV) has been developed for the treatment of newly diagnosed classical Hodgkin lymphoma (cHL), relapsed/refractory cHL, or consolidation after autologous stem cell transplantation. Notably, BV treatment combined with doxorubicin, vinblastine, and dacarbazine treatment has been established as standard treatment for newly diagnosed advanced-stage cHL. Immune-checkpoint inhibitors represent another class of promising cancer immunotherapies that may be used to treat advanced cancers, including cHL. Anti-programmed death-1-blocking antibodies have been used to enhance immunity in cases of several malignancies and obtain durable responses, most notably in patients who have been administered heavy treatment for relapsed/refractory cHL. Several clinical trials, including single agents or combination therapies for cHL, have been developed or are currently under investigation. The results of the ongoing and future clinical trials may establish new paradigms for the treatment of cHL.
尽管霍奇金淋巴瘤现已成为最可治愈的淋巴瘤之一，但一线治疗后的复发率仍保持在20%至30%。本妥昔单抗（BV）已被开发用于治疗新诊断的经典型霍奇金淋巴瘤（cHL）、复发/难治性cHL或自体干细胞移植后的巩固治疗。值得注意的是，BV治疗联合多柔比星、长春花碱和达卡巴嗪治疗已被确立为新诊断的晚期cHL的标准治疗方法。免疫检查点抑制剂是另一类有前景的癌症免疫疗法，可用于治疗包括cHL在内的晚期癌症。抗程序性死亡-1阻断抗体已被用于增强多种恶性肿瘤患者的免疫力并获得持久反应，最显著的是那些接受过针对复发/难治性cHL的强化治疗的患者。已经开展或正在进行多项针对cHL的临床试验，包括单药治疗或联合治疗。正在进行的和未来的临床试验结果可能会为cHL的治疗建立新的范例。
